Harvard Bioscience, Inc.
HBIO
$0.762
-$0.0119-1.54%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -64.06% | 37.64% | -158.20% | -46.73% | -26.43% |
| Total Depreciation and Amortization | 0.78% | 1.12% | 0.23% | -0.11% | 3.37% |
| Total Amortization of Deferred Charges | 27.14% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -14.54% | -29.55% | 34.64% | 1,070.81% | -94.30% |
| Change in Net Operating Assets | 133.46% | -192.39% | -28.51% | -33.45% | 4,425.30% |
| Cash from Operations | 0.47% | -160.30% | -67.39% | -1.33% | 22.78% |
| Capital Expenditure | -7.58% | -26.82% | 22.29% | -282.49% | 58.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -118.10% | 203.81% | 281.82% | -25.54% | -70.37% |
| Cash from Investing | -342.58% | 303.56% | 78.79% | -164.59% | 35.84% |
| Total Debt Issued | 6.56% | 22.00% | 150.00% | 0.00% | 0.00% |
| Total Debt Repaid | 67.21% | 13.43% | -8.40% | 13.33% | -1.35% |
| Issuance of Common Stock | -92.06% | 1,160.00% | -92.72% | -- | -100.00% |
| Repurchase of Common Stock | 100.00% | 74.47% | 97.73% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,088.70% | 116.78% | 74.37% | -49.67% | -15.79% |
| Foreign Exchange rate Adjustments | 9,150.00% | 102.65% | 17.49% | 5.67% | -1,041.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 351.69% | -639.29% | 97.35% | -204.04% | 89.91% |
